Tweet from AdvanceRespCare

Pharmaceutical company Pharmaxis (ASX:PXS) is pleased to announce the US Food and Drug Administration (FDA) has approved AridolTM (mannitol inhalation powder) Bronchial Challenge Test Kit for marketing.
Pharmaxis Acting Chief Executive Officer Mr Gary Phillips said, “We are extremely pleased with this achievement. An FDA submission is a complex task requiring involvement from almost all divisions of the company and this positive outcome has shown Pharmaxis’ ability to successfully work with the FDA to achieve a positive outcome.

Read More

Comments are closed.

Content Protected Using Blog Protector By: PcDrome.